TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39225437

Group type: EXPERIMENTAL
Intervention: Incidental AF during programmed electrical stimulation (PES)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Patients with incidental AF during PES
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Bradyarrhythmia risk
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias risk
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Major cardiovascular events (MACE) risk
Number of subjects: 231
Study: 39225478

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (NVX-CoV2373)
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (mRNA-1273)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: COVID-19 vaccine (AZD1222)
Number of subjects: 1299

Group type: COMPARATOR
Intervention: COVID-19 vaccine (Ad26.COV2.S)
Number of subjects: 1299
Study: 39225598

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0
Study: 39225603

Group type: EXPERIMENTAL
Intervention: Restaging MRI
Number of subjects: 277
Study: 39225612

Group type: EXPERIMENTAL
Intervention: Histotripsy treatment
Number of subjects: 44
Study: 39225647

Group type: EXPERIMENTAL
Intervention: Group 1 (ages 65 to < 75 years, n = 923 patients)
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Group 2 (ages ≥ 75 years, n = 713 patients)
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 1636

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 1636
Study: 39225670

Group type: EXPERIMENTAL
Intervention: Acamprosate (666 mg dose 3 times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 30
Study: 39225842

Group type: EXPERIMENTAL
Intervention: Online delivered running/walking group program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 72
Study: 39225890

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Current antiretroviral regimen (CAR)
Number of subjects: 493
Study: 39226027

Group type: EXPERIMENTAL
Intervention: Nudge+ (EHR documentation template plus facilitation)
Number of subjects: 46397

Group type: COMPARATOR
Intervention: Nudge (EHR documentation template only)
Number of subjects: 46397
Study: 39226070

Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.4 mg
Number of subjects: 3377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3377
Study: 39226076

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 521
Study: 39226081

Group type: EXPERIMENTAL
Intervention: Talquetamab 0.4 mg/kg weekly (QW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talquetamab 0.8 mg/kg every other week (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talquetamab Q2W
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talquetamab QW
Number of subjects: 0
Study: 39226187

Group type: EXPERIMENTAL
Intervention: Automated micro portable gas chromatography device for breath analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 60
Study: 39226237

Group type: EXPERIMENTAL
Intervention: Endovascular intervention (EVT)
Number of subjects: 0
Study: 39226247

Group type: EXPERIMENTAL
Intervention: CS-ADL (Cognitive Stimulation in Activities of Daily Living)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CS-ADL
Number of subjects: 34
Study: 39226288

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (5g per dosage, total 155g over 7 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 39226292

Group type: EXPERIMENTAL
Intervention: Low dose Tamoxifen (LDT) at 10 mg every other day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lifestyle intervention (LI, step counter use)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low dose Tamoxifen (LDT) + Intermittent caloric restriction (ICR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lifestyle intervention (LI) + Intermittent caloric restriction (ICR)
Number of subjects: 200
Study: 39226457

Group type: EXPERIMENTAL
Intervention: Thromboinflammation measured as H3Cit-DNA complexes on day 1 after STEMI
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Thromboinflammation at day 1 after STEMI
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 361
Study: 39226514

Group type: EXPERIMENTAL
Intervention: Trimodality therapy (radiation with radiosensitizing chemotherapy)
Number of subjects: 34
Study: 39226615

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 26
Study: 39226693

Group type: EXPERIMENTAL
Intervention: BLTR-3 (bilamellar tarsal rotation with a 3 mm incision height)
Number of subjects: 4914

Group type: EXPERIMENTAL
Intervention: BLTR-5 (bilamellar tarsal rotation with a 5 mm incision height)
Number of subjects: 4914

Group type: EXPERIMENTAL
Intervention: PLTR (posterior lamellar tarsal rotation)
Number of subjects: 4914

Group type: COMPARATOR
Intervention: BLTR-3
Number of subjects: 4914

Group type: COMPARATOR
Intervention: BLTR-5
Number of subjects: 4914
Study: 39226704

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) administration of 2-g TXA prehospital bolus; 11 participants
Number of subjects: 966

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 2-g TXA prehospital bolus; 334 participants
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 13 participants
Number of subjects: 966

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 299 participants
Number of subjects: 966
Study: 39226719

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Combination of TRE and LCD (TRE + LCD)
Number of subjects: 162
Study: 39227284

Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: efgartigimod IV 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Number of subjects: 0
Study: 39227399

Group type: EXPERIMENTAL
Intervention: Ad26-MVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rVSV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rVSV-booster
Number of subjects: 0
Study: 39227450

Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 215

Group type: COMPARATOR
Intervention: VMP
Number of subjects: 215
Study: 39227453

Group type: EXPERIMENTAL
Intervention: High-risk CEP72 TT genotype (rs924607)
Number of subjects: 499

Group type: COMPARATOR
Intervention: CC or CT genotypes
Number of subjects: 499
Study: 39227452

Group type: EXPERIMENTAL
Intervention: Isatuximab-bendamustine-prednisone
Number of subjects: 15
Study: 39227508

Group type: EXPERIMENTAL
Intervention: ESK981 160 mg once daily for 5 days per week for 4 weeks per cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ESK981
Number of subjects: 13
Study: 39227583

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg IV) every three weeks for two cycles
Number of subjects: 10
Study: 39227626

Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 228

Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Vitamin D adequate (> 30 ng/mL)
Number of subjects: 228
Study: 39227662

Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted stereotactic drilling drainage (MIS group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Craniotomy haematoma removal surgery (CHRS group)
Number of subjects: 67
Study: 39227769

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study: 39227818

Group type: EXPERIMENTAL
Intervention: FOS-fructans (2.1 g/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gluten (5.7 g/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 39227842

Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sarcopenia subjects before intervention)
Number of subjects: 60
Study: 39227873

Group type: COMPARATOR
Intervention: Normotensive pregnant women (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pregnant women with late-onset preeclampsia (n=30)
Number of subjects: 60
Study: 39227893

Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in delta bands at frontal and central points during rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in alpha bands at frontal and central points during rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in delta bands at central points during rest
Number of subjects: 0
Study: 39227897

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at one-month intervals
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at four-month intervals
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at six-month intervals
Number of subjects: 84
Study: 39227910

Group type: EXPERIMENTAL
Intervention: Percutaneous branch pulmonary artery interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative management for 6 months
Number of subjects: 0
Study: 39227911

Group type: EXPERIMENTAL
Intervention: Bootle Blast (8-week upper limb home-based intervention)
Number of subjects: 15
Study: 39227921

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 8 h time-restricted eating (TRE)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Combination of LCD and TRE
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 169
Study: 39227929

Group type: EXPERIMENTAL
Intervention: Non-obese with 0 CKM comorbidities (Group 1)
Number of subjects: 2105

Group type: EXPERIMENTAL
Intervention: Obese with 3 CKM comorbidities (Group 6)
Number of subjects: 2105
Study: 39228007

Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine program
Number of subjects: 0
Study: 39228063

Group type: EXPERIMENTAL
Intervention: Prenatal phenotype assessment of AKS cases (including novel case)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrops assessment in AKS cases
Number of subjects: 20
Study: 39228131

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (200/540 mg daily for 3 days)
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (40/960 mg daily for 3 days)
Number of subjects: 1526
Study: 39228660

Group type: EXPERIMENTAL
Intervention: Covered palliative (CP) stent dilation
Number of subjects: 0
Study: 39228783

Group type: EXPERIMENTAL
Intervention: Foam rolling at different speeds
Number of subjects: 18
Study: 39228845

Group type: EXPERIMENTAL
Intervention: Unmodified KF94 mask
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Unmodified KN95 mask
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Modified surgical mask
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Modified KN95 mask
Number of subjects: 100
Study: 39228858

Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa)
Number of subjects: 50
Study: 39228893

Group type: EXPERIMENTAL
Intervention: Vaccinated patients (198 cases)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Unvaccinated patients (117 cases)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Overall DKD cohort
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy (DN) group
Number of subjects: 437
Study: 39228895

Group type: EXPERIMENTAL
Intervention: Dysphagia Symptom Questionnaire (DSQ)
Number of subjects: 239
Study: 39229259

Group type: EXPERIMENTAL
Intervention: CoronaVac and IIV4 followed by PPV23
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: CoronaVac and PPV23 followed by IIV4
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: CoronaVac followed by IIV4 and PPV23
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Co-administration of IIV4 and PPV23
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: All vaccine combinations
Number of subjects: 636
Study: 39229263

Group type: EXPERIMENTAL
Intervention: Chidamide + CHOP
Number of subjects: 66

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transplanted group
Number of subjects: 66
Study: 39229468

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (150 mg) plus letrozole/anastrozole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (150 mg) plus fulvestrant
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (175 mg) plus letrozole/anastrozole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (175 mg) plus fulvestrant
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (lower doses) plus letrozole/anastrozole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dalpiciclib (lower doses) plus fulvestrant
Number of subjects: 104
Study: 39229471

Group type: EXPERIMENTAL
Intervention: Anticoagulants (primarily LMWH and direct oral anticoagulants)
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Antiplatelets (primarily aspirin)
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Any grade ⩾3 adverse events
Number of subjects: 1804
Study: 39229700

Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 217
Study: 39229707

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3986

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3986

Group type: EXPERIMENTAL
Intervention: SCAF episodes (1 to 5 episodes)
Number of subjects: 3986

Group type: EXPERIMENTAL
Intervention: SCAF episodes (≥6 episodes)
Number of subjects: 3986

Group type: EXPERIMENTAL
Intervention: Previous SCAF with no episode ≥6 minutes
Number of subjects: 3986

Group type: EXPERIMENTAL
Intervention: At least one SCAF episode in 6 months before enrollment
Number of subjects: 3986
Study: 39229786

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 39229805

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 400
Study: 39229807

Group type: EXPERIMENTAL
Intervention: Ischaemic stroke patients' experiences
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Current care strategies
Number of subjects: 9
Study: 39230120

Group type: EXPERIMENTAL
Intervention: Vibostolimab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibostolimab combined with pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibostolimab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibostolimab-based combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coformulated immunotherapy
Number of subjects: 0
Study: 39230469

Group type: EXPERIMENTAL
Intervention: Research ultrasound of the carotid arteries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveys on experience with the process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveys on perception of personal risk of stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up for changes in medical care
Number of subjects: 0
Study: 39230544

Group type: EXPERIMENTAL
Intervention: Screening for Atrial Fibrillation using a 14-day continuous electrocardiographic monitor
Number of subjects: 11905

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11905
Study: 39230545

Group type: EXPERIMENTAL
Intervention: CSL112 (6 g, 4 weekly infusions)
Number of subjects: 18119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18119
Study: 39230571

Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin plus Pembrolizumab (EV + Pembro)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Cisplatin or carboplatin plus gemcitabine (Plat + Gem)
Number of subjects: 886
Study: 39230576

Group type: EXPERIMENTAL
Intervention: Automated laminar cartilage T2 relaxation time analysis method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Manual expert analysis
Number of subjects: 72
Study: 39230668

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 103

Group type: COMPARATOR
Intervention: InSTI+TAF/FTC
Number of subjects: 103
Study: 39230672

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) for bothersome LUTS
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE) for acute urinary retention (AUR)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 478
Study: 39230678

Group type: EXPERIMENTAL
Intervention: Coaching doctors for a mean of 4.36 sessions
Number of subjects: 7254

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7254
Study: 39230757

Group type: EXPERIMENTAL
Intervention: Music intervention for 20 min each day for three consecutive days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Aromatherapy intervention for 20 min each day for three consecutive days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Music and aromatherapy combined for 20 min each day for three consecutive days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 39230829

Group type: EXPERIMENTAL
Intervention: 350/700 mg BAM + ETE
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 39230871

Group type: EXPERIMENTAL
Intervention: SCT510
Number of subjects: 567

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 567

Group type: COMPARATOR
Intervention: SCT510 and Bevacizumab
Number of subjects: 567
Study: 39230885

Group type: EXPERIMENTAL
Intervention: Aficamten (5-20 mg daily)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Aficamten
Number of subjects: 282
Study: 39230903

Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) device
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard of care (SOC) wheelchair use
Number of subjects: 161
Study: 39231015

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) screening for AF and anticoagulation upon detection
Number of subjects: 6003

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6003
Study: 39231130

Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Number of subjects: 0
Study: 39231146

Group type: EXPERIMENTAL
Intervention: Telomere Length (TL)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Telomerase Activity (TA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 84
Study: 39231213

Group type: EXPERIMENTAL
Intervention: Deep neural networks (DNNs) for activity classification
Number of subjects: 13
Study: 39231342

Group type: EXPERIMENTAL
Intervention: 750 mg of Lu AG09222
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 39231341

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Trabectedin (6 cycles)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Doxorubicin (6 cycles)
Number of subjects: 150
Study: 39231343

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 514
Study: 39231380

Group type: EXPERIMENTAL
Intervention: Intracranial implantation of SB623 cells (2.5 × 10^6 cells)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham control (surgical procedure without cell implantation)
Number of subjects: 63
Study: 39231444

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) induction therapy for 12 weeks
Number of subjects: 0
Study: 39231546

Group type: EXPERIMENTAL
Intervention: 2009 MRI+ subgroup
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Preliminary 2021 MRI+ subgroup
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 2009 MRI+ but preliminary 2021 MRI- subgroup (53/657, 8.1%)
Number of subjects: 657

Group type: COMPARATOR
Intervention: MRI- patients
Number of subjects: 657
Study: 39231549

Group type: EXPERIMENTAL
Intervention: Genetics Navigator combined with usual care by a genetics clinician (physician or counsellor)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 130
Study: 39231617

Group type: EXPERIMENTAL
Intervention: Vadadustat once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vadadustat three times weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39231735

Group type: EXPERIMENTAL
Intervention: Side-lying position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 60
Study: 39231780

Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement for adolescents and young adults (CAE-AYA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 36
Study: 39231855

Group type: EXPERIMENTAL
Intervention: Nofazinlimab 200 mg every 3 weeks (Q3W)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Nofazinlimab plus lenvatinib
Number of subjects: 107